Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's Major ITC Filing

Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's
Major ITC Filing

LAVAL, Quebec, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) the pioneer in the
krill oil industry, recently announced the filing of a complaint in the United
States International Trade Commission (the "ITC") against multiple infringers,
including Aker BioMarine ("Aker"), for infringement of U.S. Patent No.
8,278,351, which contains composition of matter claims. Aker, in a clear
attempt to shift the focus from the ITC action, has issued a press release
addressing the re-examination of a different Neptune patent that is directed
to methods of use.

"Neptune has known of the action in the re-examination of the methods of use
patent for days and recognizes it for what it is: a simple procedural step in
the long process of re-examination," said Benoit Huart, Director of Legal
Affairs of Neptune."Aker relies on the industry's inexperience with patent
litigation and is trying to sidestep the fact that Neptune has made a
significant litigation filing that allows for a fast resolution of
infringement and the potential for broad and severe remedies," he added."The
recent press release Aker issued is consistent with its strategy of
denigrating our patents to deflect attention from its infringement," he
concluded.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Asian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti Pharma Inc. ("Acasti") (TSX-V:APO)
(Nasdaq:ACST) and NeuroBioPharm Inc. ("NeuroBioPharm"), in which Neptune
respectively holds 57% and 96% of the voting rights, Neptune is also pursuing
opportunities in the medical food and prescription drug markets. Acasti and
NeuroBioPharm respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular diseases, and
for neurodegenerative and inflammation related conditions. Acasti's lead
prescription drug candidate is CaPre®, a purified high omega-3 phospholipid
concentrate derived from Neptune krill oil being developed to address the
prevention and treatment of cardiometabolic disorders, including
hypertriglyceridemia, which is characterized by abnormally high levels of
triglycerides.

Forward Looking Statements

Certain statements included in this press release may be considered
forward-looking information within the meaning of Canadian securities laws and
forward-looking statements within the meaning of U.S. federal securities laws,
both of which we refer to as forward-looking statements. Such statements
involve known and unknown risks, uncertainties and other factors that may
cause results, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Neptune's current beliefs as well as assumptions made
by and information currently available to Neptune and relate to, among other
things, Neptune's strategy, strategic goals, research and development
activities, research and clinical testing outcome, future operations, future
financial position, future revenues/results, projected costs, prospects and
plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties identified by
Neptune in its amended and restated annual information form dated September
11, 2012, in its press release announcing an action plan to resume operations
and supply customers dated November 26, 2012 and in its other public
securities filings available at www.sedar.com and www.sec.gov/edgar.shtml,
actual events may differ materially from current expectations. Except as
required by law, Neptune disclaims any intention or obligation to update or
revise any forward-looking statements.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com
        
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com